Bivalirudin
From Ganfyd
rINN: Bivalirudin
Other Names
Angiomax®
Pharmacological Information
Pharmacology Images
Web information on Bivalirudin
Mechanism of Action
Thrombin specific anticoagulant
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Bivalirudin (Less technical, good quality control)
Wikipedia on Bivalirudin (Less technical, ? quality control)
Contents |
Introduction
Clinical Use
Indications
Being developed in major indications where heparin presently used.
- Acute coronary syndrome [1]
- PCI[2]
- In patients with Heparin-induced thrombocytopenia[3]
Administration
IV bolus 0.1mg/kg followed by 0.25mg/hour in stage III trials
Clinical Issues
Contra-indications
Cautions and Interactions
Side effects
Special advice
Pharmacology
References
- ↑ Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. The New England journal of medicine 2006;355:2203-16. (Direct link – subscription may be required.)
- ↑ Matar F, Donoghue C, Rossi P, Vandormael M, Sullebarger JT, Kerenski R, et al. Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. The Canadian journal of cardiology 2006;22:1139-45.
- ↑ Almond CS, Harrington J, Thiagarajan R, Duncan CN, LaPierre R, Halwick D, et al. Successful use of bivalirudin for cardiac transplantation in a child with heparin-induced thrombocytopenia. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2006;25:1376-9. (Direct link – subscription may be required.)
